Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267733 · ClinicalTrials.gov registry record · Phase 1
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients
A Phase 1 study of Influenza and Gammopathy, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT02267733: Completed Phase 1 study of Influenza and Gammopathy, sponsored by Yale University.
NCT02267733 is a Phase 1 study of Influenza and Gammopathy that has completed, run by Yale University. The registered enrollment target is 51 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02267733, a Phase 1 study of Influenza and Gammopathy, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing schedule for patients with monoclonal gammopathies stratified by disease status
Primary Outcome
Lack of disease progression requiring therapy as measured by International Myeloma Working Group criteria
Conditions Studied
Interventions
- DRUG Fluzone
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT02267733 record still lists
NCT02267733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Fluzone is the first listed.
NCT02267733 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02267733 about?
NCT02267733 is a clinical study titled "Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients". A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing schedule for patients with monoclonal gammopathies stratified by disease status
What is the current status of trial NCT02267733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2014-10. Estimated completion is 2015-12.
What conditions does trial NCT02267733 study?
This clinical trial studies the following conditions: Influenza, Gammopathy.
What interventions are being tested in trial NCT02267733?
The interventions under investigation include: Fluzone (DRUG).
Who is sponsoring clinical trial NCT02267733?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02267733 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02267733's enrollment target sits among peer trials
51 127th of 156 higher than 29 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia